Navigation Links
Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
Date:9/4/2009

SEATTLE, Sept. 4 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the following four upcoming investor conferences.

    Rodman & Renshaw 11th Annual Health Care Conference
    Wednesday, September 9, 2009
    4:05 p.m. ET

    Morgan Stanley 2009 Global Health Care Unplugged Conference
    Tuesday, September 15, 2009
    8:35 a.m. ET

    BioCentury 16th Annual NewsMakers in the Biotech Industry Conference
    Wednesday, September 16, 2009
    1:30 p.m. ET

    UBS 2009 Global Life Sciences Conference
    Wednesday, September 23, 2009
    1:00 p.m. ET

The presentations at Rodman & Renshaw, BioCentury NewsMakers and UBS will be audio webcast live and available for replay from Dendreon's website, www.dendreon.com.

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
7. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
8. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
9. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
10. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
11. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2017)... PA (PRWEB) , ... May 19, 2017 , ... ... its QED Proof-of-Concept Program. Academic researchers with technologies ripe for commercialization, and ... New Jersey and Delaware, are encouraged to submit proposals. QED, now in its ...
(Date:5/18/2017)... ... 2017 , ... NDA Partners Chairman Carl Peck, MD , announced today ... and President of Pharmaceutical Development Business Unit of Cardinal Health, has joined the firm ... he was former Chief Operating Officer at Anaborex, Senior VP and General Manager of ...
(Date:5/18/2017)... ... 2017 , ... HOLLOWAY AMERICA, a leading manufacturer of stainless ... and pharmaceutical/biotech, recently introduced The Revolution Lift™, a new precision-controlled head lift assembly ... comes on the heels of HOLLOWAY’s release of the intelliVessel™, a smart tank ...
(Date:5/16/2017)... ... May 16, 2017 , ... Genedata, a leading ... Screener User Group Meetings, which will be held in Boston, Cambridge/UK, Shanghai, ... practices in screening data analysis and learn about the latest advances in screening ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...
Breaking Biology News(10 mins):